Our top pick for
NuVasive, Inc is a medical devices business based in the US. NuVasive shares (NUVA) are listed on the NASDAQ and all prices are listed in US Dollars. NuVasive employs 2,700 staff and has a trailing 12-month revenue of around USD$1.1 billion.
|52-week range||USD$28.55 - USD$67.7|
|50-day moving average||USD$57.3579|
|200-day moving average||USD$52.1748|
|Wall St. target price||USD$64|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.147|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing NuVasive stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NuVasive's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NuVasive's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, NuVasive shares trade at around 50x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
NuVasive's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.8341. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NuVasive's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
NuVasive's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$191.1 million.
The EBITDA is a measure of a NuVasive's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.1 billion|
|Operating margin TTM||4.78%|
|Gross profit TTM||USD$729 million|
|Return on assets TTM||1.37%|
|Return on equity TTM||-4.05%|
|Market capitalisation||USD$3.2 billion|
TTM: trailing 12 months
There are currently 3.8 million NuVasive shares held short by investors – that's known as NuVasive's "short interest". This figure is 7.5% up from 3.6 million last month.
There are a few different ways that this level of interest in shorting NuVasive shares can be evaluated.
NuVasive's "short interest ratio" (SIR) is the quantity of NuVasive shares currently shorted divided by the average quantity of NuVasive shares traded daily (recently around 768107.41482966). NuVasive's SIR currently stands at 4.99. In other words for every 100,000 NuVasive shares traded daily on the market, roughly 4990 shares are currently held short.
However NuVasive's short interest can also be evaluated against the total number of NuVasive shares, or, against the total number of tradable NuVasive shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NuVasive's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 NuVasive shares in existence, roughly 70 shares are currently held short) or 0.1152% of the tradable shares (for every 100,000 tradable NuVasive shares, roughly 115 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NuVasive.
Find out more about how you can short NuVasive stock.
We're not expecting NuVasive to pay a dividend over the next 12 months.
Over the last 12 months, NuVasive's shares have ranged in value from as little as $28.55 up to $67.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuVasive's is 1.3143. This would suggest that NuVasive's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprises products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and Precice, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.